Meta description: ViCentra has added $13 million to its Series D funding, bringing the total round to $98 million as it pushes for manufacturing scale-up and market expansion.
ViCentra has closed an additional $13 million in financing as part of its Series D round, lifting total proceeds for the round to $98 million. The Dutch medical technology company plans to use this capital to expand manufacturing, deepen its European market presence, and accelerate its regulatory pathway for entry into the US market. This update will interest founders watching late-stage growth strategies, investors tracking medtech scaling, and business leaders following diabetes technology markets.
How was this funding structured?
The new $13 million tranche follows an $85 million initial close announced in September 2025. Combined, the Series D round now totals $98 million. This elevates ViCentra’s all-time funding to approximately $200 million based on industry tracking data.
The fresh capital will be allocated toward scaling manufacturing capacity for the Kaleido insulin patch pump, expanding commercial operations in core European markets, and preparing regulatory filings for US Food and Drug Administration review.
Who invested in this round?
Funding in the second close came from Dutch investor networks, including ROM Utrecht Region and Venturing Tech. Existing backer Innovation Industries also added more capital in this tranche, demonstrating continued confidence in ViCentra’s trajectory.
Local investor participation underscores the importance of national support for advanced medical devices targeting international growth.
What does this mean for growth strategy?
Since securing the $85 million initial close, ViCentra reports doubling its European user base to over 4,000. Demand increases have prompted investments into manufacturing scale to avoid supply bottlenecks. The company aims to triple its European user base by the end of 2026, while positioning for a competitive entry into the US insulin pump space.
The Kaleido pump already holds CE marking under the European Union Medical Device Regulation, which supports its current sales in Europe. US market entry will require FDA clearance, and part of the Series D capital will fund that preparation.
Competition in the US market remains tight. In recent years, large players such as Dexcom, Abbott, and Insulet have each held significant shares in the combined insulin pump and continuous glucose monitoring segment.
FAQ
1. What is ViCentra’s total Series D funding?
ViCentra has raised $98 million in its Series D round to date.
2. How much total funding has ViCentra raised so far?
Industry data indicates total funding of around $200 million since inception.
3. Which markets are the focus for expansion?
The company is focused on Germany, the Netherlands, and France, with sights also set on entering the US.
4. What is the Kaleido insulin patch pump?
Kaleido is a wearable pump designed for type 1 diabetes management, using pulse technology for continuous micro-dosing of insulin.
Key takeaways
ViCentra’s additional $13 million in Series D funds boosts its capacity to meet rising demand and strengthens its commercial reach. Investor confidence from both new and returning stakeholders reflects momentum in European growth and readiness for US regulatory processes. For founders, the case shows how targeted scaling can be funded through staged closes, while investors can note the blend of market expansion and technical scale-up in medtech.
Disclaimer
This content is for informational purposes only and does not constitute financial advice. Readers should conduct their own due diligence before making investment decisions.